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Summary Fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy were treated with estramustine and
additionally randomized for treatment with clodronate or placebo. Clodronate treatment was started with 5 days intravenous administration
(300 mg day-') and followed by oral treatment (1.6 g day-1) for 12 months. Skeletal pain relief was only about 10% better in the clodronate
than in the placebo group. The results do not support the superiority of combined intravenous and oral treatment with clodronate compared
with oral administration only.
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Only two of the limited number of studies on treatment ofpainful
bone metastases due to prostate cancer with clodronate (Adami et
al, 1985; Adami et al, 1989; Elomaa et al, 1992; Vorreuther et al,
1992; Vorreuther, 1993; Kylmala et al, 1994; Cresswell et al,
1995) have been placebo controlled (Adami et al, 1989; Elomaa
et al, 1992). Adami and colleagues (1989) first showed, in 13
patients, that intravenous administration of clodronate was more
effective in reducing bone pain than oral administration and that
the effect lasted longer when intravenous administration was
followed by oral treatment. We have shown that oral treatment
with clodronate induces a moderate and transient pain relief in
patients with hormone-refractory prostate cancer (Elomaa et al,
1992). It was concluded that the loss ofeffect resulted partly from
dose reduction from 3.2 g to 1.6 g after the first month and partly
due to the progression ofdisease despite basic cancer treatment.
In our recently published open pilot study (Kylmala et al, 1994),
more than halfofthepatients with prostate cancer andpainful bone
metastases reported pain relief after 6 days' intravenous adminis-
tration of clodronate (300 mg day-1), and the favourable effect
lasted in all but three patients until the follow-up of3 weeks, when
the treatment was continued with oral administration (3.2 g day-').
The present study was conducted to see whether treatment with
combined intravenous and oral administration ofclodronate would
induce a more rapid and effective pain relief than the treatment
started with high oral dose. The study was prospective, random-
ized, double blinded and placebo controlled.
PATIENTS AND METHODS
The study group comprised 57 prostate cancer patients with
progressive metastatic bone disease on bone scan. All patients had
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failed first-line hormonal treatment. The characteristics of the
patients are summarized in Table 1.
The entry criteria demanded oral consent, estimated life
expectancy of at least 6 months, no signs of clinically relevant
renal or liver insufficiency, no peptic ulcer treated with antacids
and no radiation therapy in the 2 weeks preceding the trial. All
patients received estramustine phosphate (Estracyt) 280 mg twice
Table 1 Clinical characteristics of 57 patients with metastatic prostate
cancer at base line
Clodronate Placebo
Total number of patients recruited 28 29
Excluded from statistical analysis 2
Mean age (range) (years) 72 (52-81) 76 (59-86)
Duration of skeletal disease (months)
Mean (range) 9 (1-45) 16 (1-92)
Median 6 5
Treatment before the study
Orchidectomy 20 22
Oestrogen 5 7
LHRH-agonists 1 5
Antiandrogens 3 1
Radiotherapy (to the prostate) 2 0
Performance status (WHO)
0 3 1
1 13 5
2 9 10
3 3 11
4 0 0
Bone scintigraphy
Soloway 1 (< 6) 9 6
Soloway 2 and 3 (2 6) 12 14
Soloway 3 (super scan) 7 7
LHRH, luteinizing hormone-releasing hormone.
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Table 2 Performance status by number of patients on clodronate or placebo at each time point
Admission* 1 month** 3 months 6 months 12 months***
WHO Classification Clodronate Placebo Clodronate Placebo Clodronate Placebo Clodronate Placebo Clodronate Placebo
0 3 1 4 1 6 2 4 2 4 1
1 13 5 12 7 6 3 4 1 1 2
2 9 10 6 4 4 6 2 7 0 4
3 3 11 2 13 3 9 5 1 3 0
4 0 0 1 1 3 3 2 3 1 1
*P= 0.023,**P = 0.01, ***P= 0.045 between clodronate and placebo.
Table 3 The number of patients according to WHO grading for the intensity of pain (reported by doctor and by patient) and the use of analgesics according to
WHO grading scale in both treatment groups at each time point
Admission 1 month 3 months 6 months 12 months
Clodronate Placebo Clodronate Placebo Clodronate Placebo Clodronate Placebo Clodronate Placebo
Pain (doctor)
0 7 1 11 6 9 6 6 5 4 4
1 11 12 7 9 4 3 3 2 1 2
2 6 11 4 6 3 9 2 3 2 1
3 4 2 3 5 4 4 4 3 1 1
4 0 0 0 0 2 0 2 1 1 0
Pain (patient)
0 6 2 10 6 9 6 6 5 4 4
1 13 12 9 10 4 5 4 3 1 2
2 5 12 3 7 2 7 1 5 1 2
3 3 1 2 3 5 4 4 1 2 0
4 0 0 0 0 0 0 2 1 0 0
Use of analgesics
0 10 3 13 8 8 5 6 5 4 4
1 11 13 6 7 6 5 4 3 1 2
2 6 10 5 9 3 8 3 3 3 2
3 1 1 1 2 4 4 4 3 1 0
daily as basic cancer treatment. Clodronate (Bonefos, Leiras) or
matched placebo was started with 5 days of intravenous adminis-
tration (300 mg day-') and was continued by mouth
(1.6 g day-') for 12 months.
Pain, performance status and response to treatment were assessed
at admission, at 1, 3, 6 and 12 months. The intensity of pain was
assessed with a verbal ordinal scale graded from 0 (no pain) to 4
(intolerable pain) by the doctor and with a visual analogue scale
(VAS) by the patient. The use of analgesic drugs was evaluated
using a four-step grading scale (0, no analgesic drugs; 1, non-
narcotic analgesic drugs less than three time per day; 2, non-
narcotic analgesic drugs more than three times per day; 3, narcotic
analgesic drugs). Performance status was evaluated using a five-
step grading scale (0, asymptomatic; 1, minor symptoms; 2, less
than 50% ofthe time in bed; 3, more than 50% ofthe time in bed; 4,
totally bedridden). Clinical response to treatment at each follow-up
visit was assessed to be better, same or worse by the doctor.
Scintigraphies were taken at admission and at 6 and 12 months.
Response to imaging measurements was evaluated by two investi-
gators independently of each other. The number and extent of hot
spots in different sites of the skeleton were recorded according to
the Soloway grading scale (Soloway et al, 1988). The criteria for
response to treatment were formulated according to the National
Prostatic Cancer Project (NPCP; Schmidt et al, 1976) (complete
response, initially abnormal bone scan returned to normal; partial
response, a reduction of 50% in the number of hot spots and a
decrease of at least 50%, in addition to an increase of 25%, at
highest, in cross-sectional area of pre-existing lesions; progres-
sion, appearance of new hot spots and an increase of more than
25% ofthe pre-existing lesions).
Serum indices of turnover of type I collagen (the carboxy-
terminal propeptide of type I procollagen, PICP, and the pyrdino-
line-cross-linked carboxy-terminal telopeptide of type I collagen,
ICTP) were analysed at admission and at 1 and 3 months for those
patients who survived at least 3 months. The results were exam-
ined together with the measurements ofserum calcium, phosphate
and alkaline phosphatase at the corresponding time points. The
radioimmunoassays for analysing the concentrations of PICP and
ICTP were performed as described by Melkko et al (1990) and
Risteli et al (1993). PICP indicates the formation and ICTP the
breakdown oftype I collagen.
Response to basic cancer therapy (i.e. estramustine phosphate)
was evaluated by monitoring serum concentration of prostate-
specific antigen (PSA).
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All adverse events and complications, whether or not drug
related, were registered.
Fisher's exact test was used for testing categorical variables, such
as pain, use ofanalgesics andperformance status atbaseline, and for
the calculation ofthe significance ofdifferences in changes between
the treatment groups. Forthe biochemical values, the significance of
differences between the groups was calculated using the
Mann-Whitney test. The significance of changes within the treat-
ment groups was calculated using the Wilcoxon test forpaired data.
The study was approved by the local ethics committee.
RESULTS
Two patients, who refused the study medication without ever
starting it, were excluded from the statistical analyses.
Performance status and response to treatment
The performance status was better in the clodronate group at
admission (P = 0.023), at 1 month (P = 0.01) and at 12 months
(P = 0.045; Table 2), but the differences in changes between the
groups were not statistically significant at any time point of the
trial. Clinical response to treatment (evaluated by the doctor) was
assessed to be better (P = 0.055) in the clodronate group at 1
month but not after that.
Pain and use of analgesics
There was not a statistically significant difference between the
distribution ofpatients to groups according to the intensity ofpain
(reported either by doctor or patient) or according to the use of
analgesics at any time point (Table 3). Ofpatients with bone pain
(grade 1-4) at baseline, 25% were completely free of pain at 1
month in both treatment groups. At 3 months, the proportion of
such patients was 10% higher in the clodronate group. Proportions
ofpatients without analgesics at 1 month were 33% and 22% in the
clodronate and placebo groups respectively. None of these differ-
ences was statistically significant.
Response of imaging measurements
The response evaluation at 6 months showed five patients with
stable disease, nine with partial response and one with complete
response in the clodronate group. The corresponding numbers
were six, seven and one in the placebo group. At 12 months, there
was one patient with complete response on placebo, four patients
with stable disease both in the clodronate and in the placebo group
and progression of the disease in three patients on clodronate and
two patients on placebo. There were no significant differences
between the treatment groups at any time point.
Biochemistry
Serum PICP and ICTP concentrations were elevated in both
groups. The PICP values decreased slightly in both treatment
groups, whereas the ICTP values remained elevated in both
groups. The mean values of the serum calcium concentration
decreased significantly during the trial (Table 4). In the clodronate
group, the decrease was already significant at 1 month (P = 0.003),
whereas in the placebo group no earlier than at 3 months
(P = 0.044). The mean values of serum phosphate concentration
decreased markedly at 1 month in both the clodronate and the
placebo groups (P = 0.000 and P = 0.001 respectively). The
activity of serum alkaline phosphatase was highly increased in
both treatment groups at admission and increased further towards
the end ofthe trial time (Table 4).
Although there was a slight decrease at 1 month in the
clodronate group, the mean PSA concentration remained highly
increased in both treatment groups, and no patient showed a fall of
more than 50% in PSA during the course ofthe trial.
Side-effects
Nausea occurred in both groups, in particular at the beginning of
the study. At 1 month, 33% of the patients taking clodronate and
40% taking placebo reported to have experienced nausea, which
led to discontinuation of the study in two patients on clodronate
and in 1 patient on placebo. No renal failure as a result of
clodronate infusion was observed.
DISCUSSION
In this double-blind controlled study, a reduction in bone pain was
shown in both treatment groups, indicating that the basic cancer
treatment, oestramustine phosphate, induced a moderate pain
relief, although it could not control the progression ofthe disease.
Clodronate combined with estramustine phosphate was at highest
only 10% more potent than estramustine phosphate and placebo.
Regarding side-effects, nausea ccurred in both groups, suggesting
that this was mainly caused by estramustine phosphate.
Table 4 Biochemistry of patients with repeat measurements of serum PICP and ICTP at admission and at 1 and 3 months. The values are given as
mean (s.e.)
Clodronate (n = 20) Placebo (n = 19)
Measurement (reference range) Admission 1 month 3 months Admission 1 month 3 months
S-PICP (90-200 ,ug 1-') 312 (71) 151 (27) 253 (63) 285 (54) 160 (20) 163 (56)
S-ICTP (1.5-4.0,ig 1-') 10.1 (1.7) 11.2 (2.7) 12.5 (2.7) 11.9 (2.9) 10.7 (2.4) 12.9 (8.8)
S-Ca (2.20-2.65 mmol 1-') 2.27 (0.03) 2.20 (0.02)a 2.15 (0.04)b 2.22 (0.04) 2.20 (0.03) 2.15 (0.03)c
S-Pi (0.80-1.40 mmol 1-') 1.15 (0.04) 0.82 (0.04)d 0.91 (0.06)6 1.17 (0.05) 0.87 (0.03)f 0.88 (0.04)9
S-ALP (60-275 U I-') 535 (134) 687 (256)h 868 (261) 746 (226) 735 (225) 991 (370)
S-PSA (<3.0jg l-1) 161 (52) 138 (54) 226 (70) 214 (104) 258 (197) 331 (204)
a = 0.003, bp = 0.002, cp = 0.044, dp= 0.000, e-gp = 0.001, hp = 0.033; Wilcoxon's test for paired data. Differences in changes between the groups were not
significant.
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The intravenous start ofthe treatment did not improve reduction
of pain compared with treatment started with a high oral dose of
clodronate (Elomaa et al, 1992). Our results differ from previous
open studies on prostate cancer and the study of Adami and
colleagues (1989) but not from major placebo-controlled trials on
patients with advanced metastatic skeletal disease, in which
bisphosphonates seem to improve relief of bone pain by only
about 10% (Robertson et al, 1995). Such benefit from supportive
clodronate therapy remains clinically modest.
Our pilot study suggested that intravenous administration of
clodronate at the start oftreatment would induce arapid painrelief
(Kylmala et al, 1994) that could be maintained with oral treatment.
Unlike the pilot study, we did not analyse the response immedi-
ately after 5 days intravenous administration, and it may be that
the effect achieved with this was already fading at 1 month.
However, such a short effect does not support the use of intra-
venous treatment in these patients.
It was earlier concluded that clodronate has some dose-response
effect, as pain reliefoccurred in a greater proportion ofpatients and
was more marked with the dose of 3.2 g (Elomaa et al, 1992;
Kylmala et al, 1993). This may well be so, but because the gastro-
intestinal absorption of clodronate, as well as other bisphospho-
nates, is so poor (only about 2%), it seems unlikely that an
increased oral dose would have achieved higher efficacy than
intravenous administration. Thus, the dose response as an explana-
tion for the modesty and transiency ofpain reliefis not completely
satisfactory.
The majority of our patients had widespread metastatic skeletal
disease. Increase in serum PSA during the course of the trial indi-
cated insufficient response to the basic cancer treatment. It is
possible that in these patients the disease had progressed to such a
degree that normalization ofbone turnover, in particular the forma-
tion of metastatic woven bone, was no longer possible. This was
supported by the fact that treatment with neither estramustine
phosphate nor clodronate was capable of decreasing serum levels
of the collagen metabolites PICP and ICTP; although there was a
significant decrease in serum calcium, indicating inhibition of
the osteoclast-mediated resorption of mineralized bone. In our
previous publication, we reported a significant impairment of the
mineralization ofnewly formed bone in these same patients in both
treatment groups, and we concluded that this resulted from a rela-
tive deficiency of calcium and phosphate due to uncoupled bone
formation, which continued despite significant inhibition of bone
resorption (Taube et al, 1993). We assume that the loss ofpain relief
in these patients was at least partly caused by the development of
osteomalacia, as well as uncontrolled progression ofthe disease.
We conclude that intravenous administration of clodronate at
the start of treatment followed by an oral maintenance dose does
not improve the palliation of painful bone metastases due to
prostate cancer.
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